Pfizer (NYSE:PFE) has expanded its obesity drug ambitions with the acquisition of Metsera and more than 20 active clinical studies in weight management. The company also reported promising pivotal ...
Barchart on MSN
Pfizer reports strong earnings outlook - unusual call options activity shows investors are bullish
Pfizer, Inc. (PFE) reported strong earnings and earnings guidance on Feb. 3. Large, unusual call option activity today, as ...
Pfizer Inc. has acquired exclusive rights to commercialize an obesity therapy in China, strengthening its push into the ...
Pfizer (NYSE:PFE) reported positive topline Phase 3 results from its BREAKWATER oncology trial in metastatic colorectal ...
Includes a one-time $1.35 billion Acquired In-Process R&D charge related to the in-licensing agreement with 3SBio, Inc. recorded in the third quarter of 2025 with an unfavorable impact of ...
Dr. Albert Bourla, Chairman and CEO of Pfizer: “We continued to execute with focus and discipline against our strategic priorities, including strengthening our R&D organization and driving improved ...
Pfizer (PFE) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the ...
Second-quarter 2025 Cost of Sales(3) as a percentage of revenues increased by 0.9 percentage points compared to the prior-year quarter, driven primarily by the non-recurrence of a favorable revision ...
WASHINGTON, D.C. -- A major drug company is defending itself against accusations it kept promising and possibly life-saving data secret. The Washington Post reports that Pfizer decided against sharing ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results